Since CD44 is highly expressed in EOC, and is the cognate receptor for HA, we sought to enhance the delivery of TCS2210 and selectively deliver this compound to ovarian cancer cells by incorporating a CD44 targeting peptide within the nanoparticle. The gene discussed is CD44; the disease is ovarian carcinoma.